CN105431172A - 炎症性病症的治疗 - Google Patents

炎症性病症的治疗 Download PDF

Info

Publication number
CN105431172A
CN105431172A CN201480030407.7A CN201480030407A CN105431172A CN 105431172 A CN105431172 A CN 105431172A CN 201480030407 A CN201480030407 A CN 201480030407A CN 105431172 A CN105431172 A CN 105431172A
Authority
CN
China
Prior art keywords
compound
hydrocarbyl
disease
use according
nalidixic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480030407.7A
Other languages
English (en)
Chinese (zh)
Inventor
艾伦·莱斯利·罗瑟尔
杰里米·吉尔伯特·温特尔
罗伯特·亚瑟·斯科芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cresset Biomolecular Discovery Ltd
Original Assignee
Cresset Biomolecular Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201306411A external-priority patent/GB201306411D0/en
Priority claimed from GB201306413A external-priority patent/GB201306413D0/en
Application filed by Cresset Biomolecular Discovery Ltd filed Critical Cresset Biomolecular Discovery Ltd
Publication of CN105431172A publication Critical patent/CN105431172A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
CN201480030407.7A 2013-04-09 2014-04-09 炎症性病症的治疗 Pending CN105431172A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1306413.4 2013-04-09
GB201306411A GB201306411D0 (en) 2013-04-09 2013-04-09 Treatment of inflammatory conditions
GB201306413A GB201306413D0 (en) 2013-04-09 2013-04-09 The local treatment of ophthalmic diseases
GB1306411.8 2013-04-09
PCT/GB2014/051109 WO2014167327A1 (en) 2013-04-09 2014-04-09 The treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
CN105431172A true CN105431172A (zh) 2016-03-23

Family

ID=50489339

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480030407.7A Pending CN105431172A (zh) 2013-04-09 2014-04-09 炎症性病症的治疗
CN201480030418.5A Pending CN105555364A (zh) 2013-04-09 2014-04-09 炎症性眼科疾病的局部治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480030418.5A Pending CN105555364A (zh) 2013-04-09 2014-04-09 炎症性眼科疾病的局部治疗

Country Status (11)

Country Link
US (2) US20160051526A1 (cg-RX-API-DMAC7.html)
EP (2) EP2983713A1 (cg-RX-API-DMAC7.html)
JP (2) JP2016516762A (cg-RX-API-DMAC7.html)
CN (2) CN105431172A (cg-RX-API-DMAC7.html)
AU (2) AU2014252807A1 (cg-RX-API-DMAC7.html)
CA (2) CA2909111A1 (cg-RX-API-DMAC7.html)
GB (2) GB2516137B (cg-RX-API-DMAC7.html)
HK (2) HK1221166A1 (cg-RX-API-DMAC7.html)
RU (2) RU2015145135A (cg-RX-API-DMAC7.html)
WO (2) WO2014167326A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201507724B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496986A (zh) * 2014-12-12 2015-04-08 苏州亚科化学试剂股份有限公司 萘啶酸的制备方法
EP3369422A4 (en) * 2015-10-29 2018-12-05 Teika Pharmaceutical Co., Ltd. External preparation
WO2018064354A1 (en) * 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
WO2020021035A1 (en) * 2018-07-26 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antibiotics for the treatment of immunoglobulin a nephropathy
US20230058189A1 (en) * 2019-02-08 2023-02-23 Frequency Therapeutics, Inc. Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same
FI4027983T3 (fi) * 2019-09-11 2026-02-03 Adverum Biotechnologies Inc Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1228023A (zh) * 1996-08-20 1999-09-08 拜尔公司 喹诺酮羧酸或萘啶酮羧酸的口服制剂
CN1239094A (zh) * 1998-06-12 1999-12-22 拜尔公司 制备喹诺酮羧酸及其酯和萘啶酮羧酸及其酯的方法
CN1259049A (zh) * 1997-06-04 2000-07-05 伊莱利利公司 可用作5-ht1f激动剂的羧酰胺类
WO2003061767A1 (en) * 2002-01-25 2003-07-31 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
CN1259049C (zh) * 2001-07-06 2006-06-14 苏坎波公司 包含白介素-2抑制剂和抗菌剂的局部给药组合物
WO2009044141A1 (en) * 2007-10-05 2009-04-09 E-Therapeutics Plc Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti -inflammatory and the use thereof for the treatment of respiratory disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
CN1090959C (zh) * 1999-06-17 2002-09-18 卢世全 一种治疗咳喘病的中、西复方成药及制备方法
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
JP2001342188A (ja) * 2000-03-27 2001-12-11 Takeda Chem Ind Ltd 縮合ピラゾール誘導体、その製造法および用途
JP3648132B2 (ja) * 2000-06-19 2005-05-18 大正薬品工業株式会社 キノロン系抗菌薬液体製剤及びその包装体
KR101462825B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
MX2007003968A (es) * 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
EP1954800A4 (en) * 2005-12-02 2010-03-03 Health Enhancement Products In COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
US20080138350A1 (en) * 2006-10-20 2008-06-12 Bennett Michael D Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂
CN101801414B (zh) * 2007-09-21 2013-04-03 株式会社日本高度医疗研究会 口腔用和皮肤用组合物
CA2711957C (en) * 2007-10-11 2019-03-19 The Regents Of The University Of California Use of inhibitors of n-acylethanolamine-hydrolyzing acid amidase as anti-inflamatory medicaments
MX342183B (es) * 2008-09-09 2016-09-20 Allergan Inc Suspension oftalmica para uso ocular.
CN102325532B (zh) * 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
CN102711760A (zh) * 2009-08-19 2012-10-03 Mpex医药有限公司 雾化抗生素用于治疗慢性阻塞性肺病的用途
US20130079353A1 (en) * 2009-12-22 2013-03-28 Karsten Gülow Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases
EP2694048B1 (en) * 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1228023A (zh) * 1996-08-20 1999-09-08 拜尔公司 喹诺酮羧酸或萘啶酮羧酸的口服制剂
CN1259049A (zh) * 1997-06-04 2000-07-05 伊莱利利公司 可用作5-ht1f激动剂的羧酰胺类
CN1239094A (zh) * 1998-06-12 1999-12-22 拜尔公司 制备喹诺酮羧酸及其酯和萘啶酮羧酸及其酯的方法
CN1259049C (zh) * 2001-07-06 2006-06-14 苏坎波公司 包含白介素-2抑制剂和抗菌剂的局部给药组合物
WO2003061767A1 (en) * 2002-01-25 2003-07-31 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
WO2009044141A1 (en) * 2007-10-05 2009-04-09 E-Therapeutics Plc Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti -inflammatory and the use thereof for the treatment of respiratory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRSHELMANN ROLF ETAL: ""Antiinflammatory action of chemotherapeutic agents and antibiotics"", 《ZEITSHRIFT FURE DIE GESAMTE INNERE MEDIZIN UND IHRE GRENZGEBIETE》 *

Also Published As

Publication number Publication date
HK1221166A1 (zh) 2017-05-26
AU2014252808A1 (en) 2015-11-12
CA2909117A1 (en) 2014-10-16
GB2516138A (en) 2015-01-14
CA2909111A1 (en) 2014-10-16
US20160068527A1 (en) 2016-03-10
RU2015145134A (ru) 2017-05-16
EP2983788A1 (en) 2016-02-17
WO2014167327A1 (en) 2014-10-16
EP2983713A1 (en) 2016-02-17
ZA201507718B (en) 2019-11-27
US20160051526A1 (en) 2016-02-25
RU2015145134A3 (cg-RX-API-DMAC7.html) 2018-03-16
WO2014167326A1 (en) 2014-10-16
CN105555364A (zh) 2016-05-04
GB2516137A (en) 2015-01-14
JP2016516761A (ja) 2016-06-09
RU2015145135A (ru) 2017-05-12
GB201406390D0 (en) 2014-05-21
GB2516137B (en) 2016-02-17
JP2016516762A (ja) 2016-06-09
ZA201507724B (en) 2019-02-27
GB2516138C (en) 2015-12-09
GB2516138B (en) 2015-11-25
HK1221190A1 (zh) 2017-05-26
AU2014252807A1 (en) 2015-11-12
GB201406396D0 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
AU2018205077B2 (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide
US20160068527A1 (en) The Treatment of Inflammatory Disorders
AU2005247107B2 (en) Combinations comprising antimuscarinic agents and corticosteroids
JP6099609B2 (ja) 肺炎症を低減するためのレボフロキサシンの吸入
TWI475994B (zh) 阿地銨之用途
US11117865B2 (en) Inhibitors of bromodomain-containing protein 4 (BRD4)
JP2016529274A (ja) 神経疾患の処置のためのトラセミド及びバクロフェンを含む組成物
AU2003288169B8 (en) Synergistic combination comprising roflumilast and (R,R) -formoterol
CA3112796A1 (en) Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate
HK40044427A (en) Roflumilast n-oxide for use in treating autoimmune, respiratory and inflammatory disorders by inhalation
WO2005063250A1 (ja) 好中球増多抑制剤
WO2010071582A1 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
HK1217427B (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
RU2021101393A (ru) Ингибитор некроза клеток, способ его получения и применения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination